Highly Biocompatible Zwitterionic Phospholipids Coated Upconversion Nanoparticles for Efficient Bioimaging

Yao, Chunde; Wang, Peiyuan; Zhou, Lei; Wang, Rui; Li, Xiaomin; Zhao, Dongyuan; Zhang, Fan

doi:10.1021/ac5023259

Cited by 68 publications

(62 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, neutral nanoparticles, as well as those with a slight negative charge, show significantly prolonged circulating half-lives. This translates to improved accumulation in tumors, which in turn has led to recent research efforts aimed at functionalizing nanoparticles with zwitterionic surfaces 38 . Nanocarrier size also affects its in vivo fate, with larger particles (>200 nm) shown to accumulate in the liver and spleen.…”

Section: Hemorheology and Blood Vessel Fluid Dynamicsmentioning

confidence: 99%

Principles of nanoparticle design for overcoming biological barriers to drug delivery

2015

View full text Add to dashboard Cite

Biological barriers to drug transport prevent successful accumulation of nanotherapeutics specifically at diseased sites, limiting efficacious responses in disease processes ranging from cancer to inflammation. Although substantial research efforts have aimed to incorporate multiple functionalities and moieties within the overall nanoparticle design, many of these strategies fail to adequately address these barriers. Obstacles, such as nonspecific distribution and inadequate accumulation of therapeutics, remain formidable challenges to drug developers. A reimagining of conventional nanoparticles is needed to successfully negotiate these impediments to drug delivery. Site-specific delivery of therapeutics will remain a distant reality unless nanocarrier design takes into account the majority, if not all, of the biological barriers that a particle encounters upon intravenous administration. By successively addressing each of these barriers, innovative design features can be rationally incorporated that will create a new generation of nanotherapeutics, realizing a paradigmatic shift in nanoparticle-based drug delivery.

show abstract

Section: Hemorheology and Blood Vessel Fluid Dynamicsmentioning

confidence: 99%

Principles of nanoparticle design for overcoming biological barriers to drug delivery

2015

View full text Add to dashboard Cite

show abstract

“…NaGdF 4 :5%Nd@NaGdF 4 DCNPs were prepared by a successive layer-by-layer (SLBL) strategy3536 (Supplementary Fig. 2a), followed by hydrophilic modification with amphiphilic 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG2000-NH 2 ) phospholipids37. These hydrophilic DCNPs showed excellent monodispersity (∼14 nm) (Supplementary Fig.…”

Section: Resultsmentioning

confidence: 99%

In vivo gastrointestinal drug-release monitoring through second near-infrared window fluorescent bioimaging with orally delivered microcarriers

et al. 2017

Self Cite

View full text Add to dashboard Cite

Non-invasive monitoring of gastrointestinal drug release in vivo is extremely challenging because of the limited spatial resolution and long scanning time of existing bioimaging modalities, such as X-ray radiation and magnetic resonance. Here, we report a novel microcarrier that can retain drugs and withstand the harsh conditions of gastrointestinal tract. Significantly, we can track the microcarrier fate and semi-quantitatively monitor the content of drug released in vivo in real time by measuring the fluorescence signals in the second near-infrared window of lanthanide-based downconversion nanoparticles with an absorption competition-induced emission bioimaging system. The microcarriers show a prolonged residence time of up to 72 h in the gastrointestinal tract, releasing up to 62% of their content. Moreover, minimal deposition of the microcarriers is found in non-target organs, such as the liver, spleen and kidney. These findings provide novel insights for the development of therapeutic and bioimaging strategies of orally administered drugs.

show abstract

“…Recently, Zhang and coworkers developed a methodology to modify UCNPs with a new family of compact zwitterionic ligand systems composed with functional phospholipids [62] (Fig. 5.4d).…”

Section: Ligand Attractionmentioning

confidence: 99%

Surface Modification and Bioconjugation of Upconversion Nanoparticles

Zhang

2014

Nanostructure Science and Technology

Self Cite

View full text Add to dashboard Cite

One of the most important applications of upconversion nanoparticles (UCNPs) is bioapplication. A crucial issue facing the use of hydrophobic UCNPs for bioapplications is to render them water soluble and provide reactive groups for subsequent bioconjugation to various biomolecules. Surface modification can act as the bridge between the synthesis and biomedical applications of UCNPs. Surface modification of the UCNPs should not only improve the photostability of the nanoparticles with desirable interfacial properties, but also provide a potential platform for attaching biological molecules and other conjugated materials for various biomedical applications.

show abstract

Highly Biocompatible Zwitterionic Phospholipids Coated Upconversion Nanoparticles for Efficient Bioimaging

Cited by 68 publications

References 53 publications

Principles of nanoparticle design for overcoming biological barriers to drug delivery

Principles of nanoparticle design for overcoming biological barriers to drug delivery

In vivo gastrointestinal drug-release monitoring through second near-infrared window fluorescent bioimaging with orally delivered microcarriers

Surface Modification and Bioconjugation of Upconversion Nanoparticles

Contact Info

Product

Resources

About